卡培他滨联合贝伐珠单抗维持治疗转移性结直肠癌的成本效果分析
本研究基于CAIRO3三期随机临床试验(558例荷兰不可切除转移性结直肠癌患者)数据构建马尔可夫模型,从美国医保支付方角度评估卡培他滨联合贝伐珠单抗维持治疗相比观察的成本效果。结果显示维持治疗每获得一个质量调整生命年的增量成本为725,601美元,需将药物费用从每3周6173美元降至452美元(降幅93%)方具成本效果。
要点
- 维持治疗每3周增量成本为6601美元,平均每例总成本105,239美元 vs 观察组21.10美元。
- 增量成本效果比为每QALY 725,601美元,未调整的每生命年增量成本为438,394美元。
- 需将卡培他滨和贝伐珠单抗费用从6173美元降至452美元/3周(降93%)才具成本效果。
核心结论
- 卡培他滨联合贝伐珠单抗维持治疗相比观察的增量成本效果比为每QALY 725,601美元,需将药物价格降低93%才具成本效果。
研究设计与样本
- 基于CAIRO3三期随机临床试验(558例荷兰不可切除转移性结直肠癌成人患者,诱导化疗后疾病稳定或更好)数据构建马尔可夫模型,从美国Medicare支付方角度进行成本效果分析。
主要发现
- 维持治疗组平均每例成本为105,239美元,观察组为21.10美元;平均QALYs分别为1.34和1.20。
- 增量成本效果比为每QALY 725,601美元,未调整的每生命年增量成本为438,394美元。
- 敏感性分析显示成本效果随药物成本变化而变化。
- 要使每未调整生命年的增量成本效果比低于59,039美元(美国家庭收入中位数),需将卡培他滨和贝伐珠单抗费用从每3周6173美元降至452美元。
关键数值与推荐
- 增量成本效果比阈值为每QALY 725,601美元,未调整的每生命年增量成本为438,394美元。
- 成本效果阈值参考美国家庭收入中位数59,039美元/未调整生命年。
- 药物费用需从6173美元降至452美元/3周(降幅93%)以达到该阈值。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Unregulated drug prices increase cancer therapy costs. After induction chemotherapy, patients with metastatic colon cancer can receive maintenance capecitabine and bevacizumab therapy based on improved progression-free survival, but whether this treatment's cost justifies its benefits has not been evaluated in the United States. OBJECTIVE: This study sought to determine the influence of capecitabine and bevacizumab drug prices on cost-effectiveness from a Medicare payer's perspective. DESIGN, SETTING, AND PARTICIPANTS: The incremental cost-effectiveness of capecitabine and bevacizumab maintenance therapy was determined with a Markov model using a quality-of-life penalty based on outcomes data from the CAIRO phase 3 randomized clinical trial (RCT), which included 558 adults in the Netherlands with unresectable metastatic colorectal cancer who had stable disease or better following induction chemotherapy. The outcomes were modeled using Markov chains to account for patients who had treatment complications or cancer progression. Transition probabilities between patient states were determined, and each state's costs were determined using US Medicare data on payments for capecitabine and bevacizumab treatment. Deterministic and probabilistic sensitivity analyses identified factors affecting cost-effectiveness. MAIN OUTCOMES AND MEASURES: Life-years gained were adjusted using CAIRO3 RCT quality-of-life data to determine quality-adjusted life-years (QALYs). The primary end point was the incremental cost-effectiveness ratio, representing incremental costs per QALY gained using a capecitabine and bevacizumab maintenance regimen compared with observation alone. RESULTS: Markov model estimated survival and complication outcomes closely matched those reported in the CAIRO3 RCT, which included 558 adults (n = 197 women, n = 361 men; median age, 64 and 63 years for patients in the observation and maintenance therapy groups, respectively) in the Netherlands with unresectable metastatic colorectal cancer who had stable disease or better following induction chemotherapy. Incremental costs for a 3-week maintenance chemotherapy cycle were $6601 per patient. After 29 model iterations corresponding to 60 months of follow-up, mean per-patient costs were $105 239 for maintenance therapy and $21.10 for observation. Mean QALYs accrued were 1.34 for maintenance therapy and 1.20 for observation. The incremental cost-effectiveness ratio favored maintenance treatment, at an incremental cost of $725 601 per QALY. The unadjusted ratio was $438 394 per life-year. Sensitivity analyses revealed that cost-effectiveness varied with changes in drug costs. To achieve an incremental cost-effectiveness ratio of less than $59 039 (median US household income) per unadjusted life-year would require capecitabine and bevacizumab drug costs to be reduced from $6173 (current cost) to $452 per 3-week chemotherapy cycle. CONCLUSIONS AND RELEVANCE: Antineoplastic therapy is expensive for payers and society. The price of capecitabine and bevacizumab maintenance therapy would need to be reduced by 93% to make it cost-effective, a finding useful for policy decision making and payment negotiations.
引用
- Sherman SK, Lange JJ, Dahdaleh FS, et al. Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer. JAMA Oncol. 2019. PMID: 30489611. doi:10.1001/jamaoncol.2018.5070
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。